Annals of the Rheumatic Diseases ARD_BMJ
2 years 4 months ago
Major pathogenic characteristics of #Sjogren disease
#EULAR2024
CB https://t.co/3NeBBKIVT4
Annals of the Rheumatic Diseases ARD_BMJ
2 years 4 months ago
Did the patient fail on therapy or are the therapies failing the patient? š¤
Difficult to to manage psoriatic arthritis: A suggested approach
#EULAR2024
NZ https://t.co/lYvXEX7dp3
Peter Nash drpnash
2 years 4 months ago
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
Janet Pope Janetbirdope
2 years 4 months ago
#Editorās #Choice
@MatsJunek
Who #relapses in
#ANCA #vasculitis
In #Pexivas trial
#Renal #failure may be protective from relapses.
Seems to be the case in renal #lupus #GN too~my opinion
?Why š¤·
#EULAR2024 #EULARBEST @ARD_BMJ
@RheumNow @eular_org @ACR_Journals https://t.co/kUD1qjnwqE
David Liew drdavidliew
2 years 4 months ago
I was allocated to bring down the warning, & I did apologise up front to both the EMA and Janet #EULAR2024. It's a tough gig regulating impactful medicines with risk-benefit, especially when our world is full of other medicines with risk-benefit trade-offs (like prednisolone). 2/ https://t.co/6YPhYHbhg8
David Liew drdavidliew
2 years 4 months ago
So how do we get from slightly increased numbers of uncommon events in a single study (ORAL Surveillance)?
Regulators think differently to us, which partly is the difficulty of a restrictive warning.
So being the Aussie I am, I asked - does it pass the 'pub test'? 4/ #EULAR2024 https://t.co/Ih9H87wH22
David Liew drdavidliew
2 years 4 months ago
Having said that, the EMA warning has elements making it extremely tough:
- still very broad criteria that capture 80% of people who were starting JAKi
- the need for "no suitable treatment alternatives" before using a JAKi, right across all diseases (not just RA) 3/ #EULAR2024 https://t.co/IsrYO7qzqM
David Liew drdavidliew
2 years 4 months ago
So I think there is plenty we could do instead.
better regulation
better risk stratification
better counselling
better risk factor management
(and definitely read this if you want to be a good clinician: https://t.co/RA6ktQB7gm)
18/ #EULAR2024 https://t.co/bC5nmi8SoM
- The Art of Communicating Risk and Benefit to Promote Shared DecisionāMaking, Inā¦
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
David Liew drdavidliew
2 years 4 months ago
My friend the late, great @philipcrobinson and I wrote @TheLancetRheum about what we could learn from COVID about preventative medicine.
https://t.co/55j8rduvyn
It's worth us thinking how we can do better by our patients.
18/ #EULAR2024 https://t.co/zlDKYngsu0
David Liew drdavidliew
2 years 4 months ago
Here's my 'pub test' for whether the warning is appropriate. And, debate aside, I do believe that it behoves any regulator to consider the unintended consequences of their regulation, because regulation has real consequences. 5/ #EULAR2024 https://t.co/aurbAwgl9P
Bella Mehta bella_mehta
2 years 4 months ago
The original direct comparison study! https://t.co/hqrPKfNW1y
Bella Mehta bella_mehta
2 years 4 months ago
Computer vision/ image analysis is performing very well in rheumatology and can extend help to low resource settings easily! #EULAR2024 https://t.co/8doM7foriM
Bella Mehta bella_mehta
2 years 4 months ago
SLE RPI may be used more frequently
and can connect the digital dots! @RheumNow https://t.co/UdVIyZJhJV
Bella Mehta bella_mehta
2 years 4 months ago
Deep learning models are detecting CPPD in radiographs pretty well!! Abst#0112 #EULAR2024 presented by @ThomasHugle ...@RheumNow https://t.co/9z3VVbyyh0
